Julie M. Vose, MD, MBA | Authors

SAENZ MEDICAL PHARMACY

2121 E GRIFFIN PKWY STE 18

Articles

Minority Enrollment to Clinical Trials: Road to Increased Access

March 14, 2021

ONCOLOGY co–Editor-in-Chief Julie M. Vose, MD, MBA, details how underrepresentation of racial and ethnic minorities in clinical trials negatively impacts the medical community and calls for greater inclusion by removing some barriers to participation.

WANTED: An “All-Out” National Vaccination Program

February 02, 2021

Unprecedented efforts from researchers and pharmaceutical engineers have brought about safe, effective vaccines, in record development times; now the focus must be on a federally coordinated program to administer those injections in the most efficient manner possible.

Use of Real-World Evidence in Hematology/Oncology Treatment Optimization

November 13, 2020

Accurate and well maintained patient-level data is needed to gather and formulate real-world evidence that is necessary to optimize existing treatment and shape future treatment for patients with hematological malignancies.

Understanding Evaluation and Management of Primary Cutaneous and Systemic ALCL

June 15, 2010

Querfeld et al have written a comprehensive evaluation of primary cutaneous and systemic anaplastic large cell lymphoma (ALCL). The important similarities between them are outlined in the article, for example tumor cells expressing the CD30 antigen for both subtypes. In addition, important differences such as the wide spectrum of CD30+ lymphoproliferative disorders of the skin and the large differences in outcomes of the primary cutaneous vs systemic types of ALCL are discussed. Other important differences include expression of the anaplastic lymphoma kinase (ALK) protein. The ALK protein is activated most frequently through the nonrandom t(2;5) chromosome translocation, resulting in fusion of the nucleophosim (NPM) gene located at 5q35 to 2p23 and encoding the receptor tyrosine kinase, ALK. Most patients with primary cutaneous ALCL are ALK-negative, yet their 5-year disease-free survival rate is > 90%. Systemic ALCL is divided into ALK-positive and ALK-negative cases. Patients with systemic ALCL that is ALK-positive have a much higher 5-year survival rate of 70%, compared with a rate of 49% for those with systemic ALCL that is ALK-negative.[1]